Evidence map›Paper›PMID 41462342›Full record

ArticleParasites & vectors2025

Design, synthesis, and anti-Toxoplasma gondii evaluation of β-carboline derivatives.

Zhendi Liu, Yongmei Li, Yetian Li, Xiaoyu Han, Hongda Qiu, Chang Qin, Yuchao Zhu, Weida Liang, Jiao Mo, Zixun Yan and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zhendi LiuSchool of Basic Medical Sciences, Health Science Centre, Ningbo University, Ningbo, 315211, China.
Yongmei LiKey Laboratory of Advanced Mass Spectrometry and Molecular Analysis of Zhejiang Province, School of Materials Science and Chemical Engineering, Ningbo University, Ningbo, 315211, China.
Yetian LiSchool of Basic Medical Sciences, Health Science Centre, Ningbo University, Ningbo, 315211, China.
Xiaoyu HanSchool of Basic Medical Sciences, Health Science Centre, Ningbo University, Ningbo, 315211, China.
Hongda QiuKey Laboratory of Advanced Mass Spectrometry and Molecular Analysis of Zhejiang Province, School of Materials Science and Chemical Engineering, Ningbo University, Ningbo, 315211, China.
Chang QinSchool of Basic Medical Sciences, Health Science Centre, Ningbo University, Ningbo, 315211, China.
Yuchao ZhuDepartment of Radiology, First Affiliated Hospital of Ningbo University, Ningbo, 315010, China.
Weida LiangKey Laboratory of Advanced Mass Spectrometry and Molecular Analysis of Zhejiang Province, School of Materials Science and Chemical Engineering, Ningbo University, Ningbo, 315211, China.
Jiao MoSchool of Basic Medical Sciences, Health Science Centre, Ningbo University, Ningbo, 315211, China.
Zixun YanSchool of Basic Medical Sciences, Health Science Centre, Ningbo University, Ningbo, 315211, China.
Weixin GaoSchool of Basic Medical Sciences, Health Science Centre, Ningbo University, Ningbo, 315211, China.
Jiyu ZhangLanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Lanzhou, 730046, China.
Jishan ZhengNingbo Women and Children's Hospital, Ningbo, 315012, Zhejiang, China.
Hongze LiangKey Laboratory of Advanced Mass Spectrometry and Molecular Analysis of Zhejiang Province, School of Materials Science and Chemical Engineering, Ningbo University, Ningbo, 315211, China. lianghongze@nbu.edu.cn.
Jili ZhangSchool of Basic Medical Sciences, Health Science Centre, Ningbo University, Ningbo, 315211, China. zhangjili@nbu.edu.cn.

Funding

Ningbo Natural Science Foundation 2021J251Ningbo Natural Science Foundation 2024J465One Health Interdisciplinary Research Project, Ningbo University HY202402
6 · The paper itself

Abstract

backgroundThe current therapeutic options for toxoplasmosis are limited by side effects. The development of molecules against T. gondii is urgently needed. A series of β-carboline derivatives were synthesized and examined as potential agents against toxoplasmosis.

methodsA series of β-carboline derivatives were synthesized. To assess their potential as anti-T. gondii agents, cytotoxicity towards Vero cells was determined using the CCK-8 assay. Plaque and qPCR assays were carried out to screen for anti-T. gondii activities, providing insights into their inhibitory effects on the parasite. In vitro assays on T. gondii RH and PRU strains were conducted to evaluate proliferation, invasion, and cyst formation. Transmission electron microscopy was employed to analyze ultrastructural changes and apoptosis in T. gondii, revealing the impact of the derivatives at the cellular level. Finally, the in vivo efficacy of the derivatives was tested in a mouse model, which offered valuable information on their potential therapeutic effects in a living organism.

resultsβ-carboline derivatives exhibited potent inhibitory effects on the growth and replication of both PRU and RH strains, while demonstrating low cytotoxicity to mammalian cells. It is worth noting that NBZ023 and NBZ035 exhibited optimal potency against proliferation (IC

conclusionsLead compounds NBZ023 and NBZ035 exhibited an excellent overall efficacy against the T. gondii RH and PRU strains, and were highly effective at preventing toxoplasmosis during murine infection, which are expected to be developed as new anti-toxoplasmosis drugs.

Indexed as

Antiprotozoal AgentsCarbolinesToxoplasmaToxoplasmosisAnimalsChlorocebus aethiopsDisease Models, AnimalDrug DesignFemaleMiceMice, Inbred BALB CToxoplasmosis, AnimalVero CellsAntiprotozoal AgentsCarbolinesIn vitroIn vivoToxoplasma gondiiβ-carboline derivatives

Identifiers

PMID41462342
PMCPMC12750888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.